To estimate the association of changes of a shift in Medicare Part B to Part D with total drug spending and patient cost-sharing. 
I n 2016, Medicare Part B spending for prescription drugs was $29.1 billion, primarily for medications administered by injection or infusion in physician offices and hospital outpatient departments. 1 Between 2010 and 2016, Medicare Part B drug spending increased by approximately 9.8% on average per year, compared with an average annual growth rate of 8.2% in Medicare Part D program expenditures. 1, 2 In May 2018, the US Department of Health and Human Services (HHS) proposed to shift coverage of certain drugs from Part B to Medicare Part D.
3,4 Both programs cover outpatient prescription drugs but pay for them differently. In Part B, Medicare payments are based on the average sales price, which is the price paid (net of discounts and rebates) by most private purchasers, plus a statutory add-on amount. In Part D, private insurers administer prescription drug plans for Medicare beneficiaries; individual Part D plans (and their pharmacy benefit managers) negotiate with manufacturers to determine the amounts they pay for drugs. The HHS policy blueprint 5 was published on May 11, 2018.
The proposed Medicare Part B reform is an important part of the Trump administration's strategy to lower drug prices and reduce out-of-pocket costs for Medicare beneficiaries. 4 We modeled the effects of the proposed reform on total drug spending and patients' out-of-pocket costs for prescription drugs.
Methods
We obtained Part B drug utilization, patient cost-sharing, and total spending data from the Centers for Medicare & Medicaid Services (CMS) Drug Data files, which cover fee-forservice claims. 6 These data files summarize Part B drug claims from physicians, outpatient hospitals, and suppliers, and exclude claims billed using NOC codes ("Not Otherwise Classified") (eg, J3490, J3590, or J9999), claims for which Medicare was not the primary payer, and claims with total spending amounts of $0 associated with the drug (see eMethods in the Supplement). 6 The study drug cohort comprised brandname drugs associated with the highest Part B expenditures, defined as brand-name drugs with at least $10 million in Part B spending in 2016 (most recent year of data available). Generic drugs, devices, vaccines, blood products and clotting factors, and certain biological products were excluded (eMethods in the Supplement). The Medicare Prescription Drug Benefit Manual states that Part D plan sponsors must include "all or substantially all" drugs in the 6 protected classes in their formularies. 7 The protected classes are immunosuppressants for prophylaxis of organ transplant rejection, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. (1) fully protected class-all approved indications were in a protected class (eg, bortezomib indicated for multiple myeloma and mantle cell lymphoma); (2) partially protected class-at least 1 indication was in a protected class (eg, rituximab indicated for various cancers), but there were some indications that were not in a protected class (eg, rituximab indicated for rheumatoid arthritis); and (3) not protected class-all approved indications were not in a protected class (eg, omalizumab indicated for asthma and chronic idiopathic urticaria). After independent review, the final classifications were made by consensus. Current annual drug costs were priced for Part B using Medicare's quarterly ASP (Average Sales Price) Drug Pricing file 10 and for Part D using wholesale acquisition costs, which were a median 5.0% to 6.8% lower than reported standard pharmacy costs as of July 2018 (eMethods in the Supplement).
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Total drug spending in Part B and Part D was estimated using current prices for each program and unadjusted utilization (number of units and beneficiaries) per drug from the latest Medicare Drug Data files. Since Part B drug costs and spending estimates already include rebates, we estimated "net," or rebate-adjusted, drug spending in Part D after accounting for manufacturer rebates and the coverage gap discount (manufacturers provide a 50% discount on drug costs in the coverage gap phase of Part D) ( 13 Based on these, Part D spending was adjusted for rebates using an average rebate range of 20.0% to 30.0% for spending on drugs that were not in a protected class and an average rebate range of 0% to 10.0% for spending on drugs in any of the protected classes. Medicare's estimated reinsurance subsidy obligation (that is, reinsurance payments by Medicare to Part D plans) was also adjusted for rebates, using the agency's allocation methodology 14 and a shared rebate fraction of 30.0% to 40.0%. 15 To validate these estimates, in a sensitivity analysis, we also assessed total rebate-adjusted spend- Meaning Although the HHS proposal may reduce total drug spending, it could increase out-of-pocket costs for some Medicare beneficiaries.
Key Points
ing using drug-specific rebate levels estimated by SSR Health LLC, an investment research firm; SSR's rebate estimates were available for 45 (60%) of the 75 studied drugs (eMethods in the Supplement). 16 For each drug in the study cohort, we projected annual outof-pocket costs under current drug prices and the standard 2018 Part D benefit (Table 1) as the base case. Ranges in projected Part D out-of-pocket costs were constructed by varying the coinsurance from 25.0% (standard) to the maximum 33.0% allowable for specialty drugs (defined by Medicare as monthly costs exceeding $670), 17 and by varying annual outof-pocket costs in Part D on drugs other than the Part B agent from $0 to $1169 (beneficiaries in the top 5% of spending).
18
Current Part B cost-sharing was estimated using current prices and actual cost-sharing amounts (as a percentage of spending) and annual utilization extracted from the Medicare Drug Data files. In the primary analysis, differences in Since the HHS proposal suggested that drugs with lower prices in other countries could be prioritized for the shift from Part B to Part D, 3,5 we compared drug prices between the United
States and other countries and considered changes in out-ofpocket costs for these products. In secondary analyses, we examined subsets of drugs in the study cohort to align with policy scenarios proposed by HHS: (1) drugs with prices exceeding the median of those in comparator high-income countries (Germany, Japan, Switzerland, and the United Kingdom); (2) drugs covered by both Part B and Part D; and (3) specialty drugs. Descriptive statistics were calculated using Stata version 12.0 (StataCorp Inc).
Results
The Table 2) .
In an advance notice of proposed rulemaking published on October 25, 2018, CMS suggested that Part B drug prices were among the highest in the world and considered directly reducing expenditures for Part B drugs to more closely reflect other countries. Therefore, to assess the magnitude of these price differences, we compared drug prices in Part B and comparator high-income countries. For 67 drugs with available information, 65 (97.0%) had higher prices in Part B than the median of prices in comparator high-income countries. As of May 2018, drug prices in other high-income countries were a median of 45.8% to 59.7% lower than those in Part B ( Figure) . Table 4 ). The threshold annual drug cost, for which costsharing in the standard Part D benefit would be lower than the coinsurance in Part B, was $15 869 (eFigure 2 in the Supplement). In secondary analyses, results were similar for the scenarios when drugs with prices exceeding the median of prices in comparator high-income countries or drugs covered by both Part B and Part D were shifted to Part D (Table 4) . Out-ofpocket costs were estimated to increase for fewer drugs (2-9 drugs, 3.6%-16.4% vs 22-29 drugs, 29.3%-38.9%) if HHS shifted only specialty drugs to Part D. We also descriptively assessed cost-sharing for the study drugs for 3 additional categories of Medicare beneficiaries. First, for those qualifying for the low-income subsidy program (approximately 5%-10% of fee-for-service Medicare beneficiaries), cost-sharing for brand-name drugs would be $0 to $8.35, depending on income and resources (eMethods in the Supplement). Second, the national average annual premium cost for Medigap insurance was $2216 in 2016. 
Discussion
The HHS proposed reforms seek to expand the role of privatesector negotiation of Medicare drug prices by shifting coverage of certain drugs from Part B to Part D. Consistent with the administration's advance notice of proposed rulemaking, we found that drug prices in other high-income countries were substantially lower than Part B drug prices. 22 We estimated that the proposed policy shift from Part B to Part D could reduce total drug spending by 6.9% to 18.3% after accounting for rebates and discounts. However, the potential for greater overall savings was constrained by the fact that 33 (44.0%) of the studied brand-name drugs were in protected classes, which HHS has reported precludes meaningful price negotiation by Part D plans. 
Weighted average Median
The ex-factory price for the selected comparator countries is the price exclusive of sales tax and value-added taxes and adjusted for statutory rebates (but excludes confidential managed access and performance-based rebates in the United Kingdom). Illustrated weighted average ratios are weighted at the drug level by 2016 Medicare Part B expenditures. ASP indicates average sales price; the US ASP = 1. Prices were converted to US dollars at spot exchange rates as of in the medium to long-term, the expanding reinsurance component of the Part D benefit may attenuate-or potentially even eliminate-the incentive for Part D plans to obtain the lowest drug costs for beneficiaries and the government.
23-25
Our analysis also indicates that the proposed policy reform could have a material impact on patients' out-of-pocket costs, with effects varying by drug and patients' insurance in addition to Medicare. We estimated that moving drug coverage from Part B to Part D could decrease out-of-pocket costs among patients without supplemental insurance for the majority of drugs, while increasing cost-sharing for 29.3% to 38.9% of products (22-29 drugs) (or 3.6%-16.4% if limited to highcost specialty drugs; 2-9 drugs). The favorable impact of this policy shift on cost-sharing would be greatest for beneficiaries who qualify for the Part D low-income subsidy, which can eliminate the coinsurance liability based on income and resources. By contrast, for patients with Medigap insurance, outof-pocket costs in Part D were estimated to exceed the annual premium costs for supplemental insurance for 62.7% to 74.7% of drugs (47-56 drugs). Out-of-pocket costs would be increased under the proposed policy for beneficiaries with Medigap but without Part D coverage.
Limitations
Our study has limitations. First, the study did not account for possible effects of this proposed reform on insurance premiums or drug utilization. Further actuarial analysis is needed to more precisely determine the financial impact by stakeholder (eg, incurred costs for Medicare vs Part D plans). Second, the study did not include beneficiaries dually eligible for Medicare and Medicaid (who would likely have no or minimal change in cost-sharing due to eligibility for the lowincome subsidy in Part D) or those enrolled in employersponsored retiree health plans. The HHS proposal would also c Calculated as a proportion of Part B drugs for which foreign prices were available (n = 67); comparator high-income countries were Germany, Japan, Switzerland, and United Kingdom; 2 enzyme-replacement therapies (velaglucerase alfa and imiglucerase) were less expensive in the United States.
d Specialty drugs are defined by Medicare as those with monthly costs exceeding $670.
likely only apply to fee-for-service Medicare, which covers roughly 67% of Medicare beneficiaries. which is consistent with our estimate for fee-for-service Medicare. Finally, while rebate amounts are confidential, we used current disclosures from HHS and insurers, as well as an industry database of drug-specific rebate amounts, as the best available estimates of Part D rebate levels, and our estimates are in line with those from prior studies. 28 Final incurred net costs in Part D may differ from the estimates presented here.
Conclusions
The limitations of the present study are unlikely to substantially change the overall conclusion that significant savings For the secondary analysis of drugs with prices exceeding median of comparator high-income countries, we used standard recognized sources to identify comparable drug prices (net of statutory rebates) for Germany, Japan, Switzerland, and United Kingdom. 
Part D Drug Rebates
We estimated net Part D drug spending after rebates and the coverage gap discount program. Reported Part D rebate levels were obtained from three sources, all published in 2018: (1) the 2018 Medicare Trustees Report, which projected rebates would account for 25.3% of total drug costs in 2018; (2) an industry-sponsored analysis of five Part D plans, which reported an average rebate of 4% for all protected class drugs and 14% among the subset of protected class drugs with any rebate; and (3) a HHS disclosure that the average rebate for protected class drugs was approximately 6%. Thus, an average rebate of 20% to 30% was applied for spending on drugs not in protected classes and an average rebate of 0% to 10% for spending on drugs in protected classes. For the coverage gap discount program, the share of applicable beneficiaries was assumed to be 70%. For the reinsurance subsidy obligation, the average proportion of direct and indirect remuneration (i.e., rebates) reducing government liability, as compared to total plan and government liability, was assumed to range from 30% to 40%.
In a sensitivity analysis, we repeated our analysis with drug-specific rebate estimates from a comprehensive US drug pricing database developed by SSR Health, an investment research firm.
6 7 SSR Health uses publicly reported and commercially proprietary sales data to estimate total gross and net sales at the drug unit level. This database, which is updated quarterly and covers over 95% of US net sales for brand-name drugs, is limited to drugs marketed by publicly traded companies; price and volume data may not be consistently available for products with low (or unreported) sales or those with restricted or highly specialized distribution channels. Overall, rebate estimates were available for 45 (60%) of the drugs in our study cohort. For each drug, to smooth possible quarter-toquarter volatility in inventory and net sales, we extracted trailing four-quarter total average rebate rates as of the second quarter ended June 30, 2018. 
